To print: Select File and then Print from your browser's menu

Title: FDA Issues Approvable Letter for Ambien CR (Zolpidem Tartrate Extended Release) CIV for the Treatment of Insomnia

"FDA Issues Approvable Letter for Ambien CR (Zolpidem Tartrate Extended Release) CIV for the Treatment of Insomnia"

PARIS, FRANCE -- April 11, 2005 -- Sanofi-aventis announced today that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) for Ambien CR™ (zolpidem tartrate extended release) CIV. Ambien CR™ is the controlled-release formulation of zolpidem, the world's leading sleep aid. An approvable letter outlines specific questions that have to be resolved before the Agency will approve a product for marketing. Sanofi-aventis Group is already working closely with the FDA to address the questions outlined in the letter. The FDA's questions relate specifically to Ambien CR and are not related to the safety and efficacy of Ambien® (zolpidem tartrate). About Ambien Ambien is indicated for the short-term treatment of insomnia. There is a low occurrence of side effects associated with the short-term use of Ambien. The most commonly observed side effects in controlled clinical trials were drowsiness (2%), dizziness (1%), and diarrhea (1%). When you first start taking Ambien, use caution in the morning when engaging in activities requiring complete alertness until you know how you will react to this medication. In most instances, memory problems can be avoided if you take Ambien only when you are able to get a full night's sleep (7 to 8 hours) before you need to be active again. As with any sleep medication, do not use alcohol while you are taking Ambien. Prescription sleep aids are often taken for 7 to 10 days-or longer as advised by your doctor. All people taking sleep medicines have some risk of becoming dependent on the medicine. For full prescribing information, please visit http://www.ambien.com SOURCE: sanofi-aventis

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.